These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 9029320)

  • 1. Determination of ebrotidine and its metabolites in human urine by reversed-phase ion-pair high-performance liquid chromatography.
    Rozman E; Galcerán MT; Albet C
    J Chromatogr B Biomed Sci Appl; 1997 Jan; 688(1):107-15. PubMed ID: 9029320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolism of ebrotidine. A review.
    Rozman E; Albet C; Sacristán A; Ortiz JA
    Arzneimittelforschung; 1997 Apr; 47(4A):486-9. PubMed ID: 9205749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of ebrotidine and its metabolites by micellar electrokinetic capillary chromatography.
    Sentellas S; Puignou L; Galceran MT
    J Chromatogr A; 2002 Nov; 976(1-2):221-7. PubMed ID: 12462613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolites of ebrotidine, a new H2-receptor antagonist, in human urine.
    Rozman E; Galcerán MT; Anglada L; Albet C
    J Pharm Sci; 1994 Feb; 83(2):252-4. PubMed ID: 7909553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigation of the metabolism of ebrotidine in human urine by liquid chromatography-atmospheric pressure chemical ionization mass spectrometry.
    Rozman E; Galceran MT; Anglada L; Albet C
    Drug Metab Dispos; 1995 Sep; 23(9):976-81. PubMed ID: 8565788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic study of ebrotidine administered in multiple doses to healthy volunteers for 4 days.
    Frías J; Esteban C; Carcas AJ; Sánchez-García P; Albet C; Torres J; Márquez M; Ortiz JA
    Arzneimittelforschung; 1997 Apr; 47(4A):531-4. PubMed ID: 9205759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of ebrotidine in healthy volunteers. A summary.
    Albet C; Pérez JA; Rozman E; Márquez M; Herrero E; Ortiz JA
    Arzneimittelforschung; 1997 Apr; 47(4A):535-9. PubMed ID: 9205760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determination of ebrotidine and its metabolites by capillary electrophoresis with UV and mass spectrometry detection.
    Sentellas S; Puignou L; Moyano E; Galceran MT
    J Chromatogr A; 2000 Aug; 888(1-2):281-92. PubMed ID: 10949494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histamine H2-receptor antagonist action of ebrotidine. Effects on gastric acid secretion, gastrin levels and NSAID-induced gastrotoxicity in the rat.
    Palop D; Agut J; Márquez M; Conejo L; Sacristán A; Ortiz JA
    Arzneimittelforschung; 1997 Apr; 47(4A):439-46. PubMed ID: 9205740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gastric acid inhibitory profile of ebrotidine, a novel H2-receptor antagonist in humans.
    Maczka M; Kwiecień N; Obtułowicz W; Konturek SJ; Kamiński K; Oleksy J; Gabryelewicz A; Torres J
    J Physiol Pharmacol; 1992 Jun; 43(2):139-48. PubMed ID: 1356519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Ebrotidine in the eradicating treatment of H. pylori].
    Fernández Bermejo M; García Grávalos R
    Gastroenterol Hepatol; 1998; 21(6):316. PubMed ID: 9711019
    [No Abstract]   [Full Text] [Related]  

  • 12. Allergic dermatitis due to oral ebrotidine.
    Carretero Aníbarro P; Blanco Carmona J; García González F; Garcés Sotillos M; Herrero Gil D; Pérez Giménez R; Juste Picón S
    J Investig Allergol Clin Immunol; 1999; 9(3):193-4. PubMed ID: 10412683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the efficacy and safety of ebrotidine in the treatment of duodenal ulcer. A multicentre, double-blind, placebo-controlled phase II study.
    Gabryelewicz A; Czajkowski A; Skrodzka D; Marlicz K; Luca de Tena F; Aldeguer M; Chantar C; Márquez M; Torres J; Ortiz JA
    Arzneimittelforschung; 1997 Apr; 47(4A):545-50. PubMed ID: 9205762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-Helicobacter pylori activities of ebrotidine. A review of biochemical and animal experimental studies and data.
    Slomiany BL; Piotrowski J; Slomiany A
    Arzneimittelforschung; 1997 Apr; 47(4A):475-82. PubMed ID: 9205747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficient high-performance liquid chromatographic assay for the simultaneous determination of metoprolol and two main metabolites in human urine by solid-phase extraction and fluorescence detection.
    Chiu FC; Damani LA; Li RC; Tomlinson B
    J Chromatogr B Biomed Sci Appl; 1997 Aug; 696(1):69-74. PubMed ID: 9300910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tolerability and pharmacokinetics of ebrotidine in healthy subjects given single and repeated oral doses.
    Farré M; Roset PN; Badenas JM; Ugena B; Márquez M; Albet C; Herrero E; Ortiz JA
    Arzneimittelforschung; 1997 Apr; 47(4A):528-30. PubMed ID: 9205758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ebrotidine.
    Patel SS; Wilde MI
    Drugs; 1996 Jun; 51(6):974-80; discussion 981. PubMed ID: 8736619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HPLC reveals famotidine in the urine up to five days after a single 20 mg oral dose.
    Bologna M; Napolitano T; Biordi L; Carlucci G
    Drugs Exp Clin Res; 1988; 14(6):419-21. PubMed ID: 2905638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physicochemical properties, analytical determinations and stability of ebrotidine.
    Albet C; Fernández JM; Castelló JM; Sacristán A; Ortiz JA
    Arzneimittelforschung; 1997 Apr; 47(4A):435-8. PubMed ID: 9205739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination of angiotensin II receptor antagonist (E4177) in human plasma and urine by high-performance liquid chromatography.
    Seki T; Yamazaki K; Kayano M
    J Chromatogr B Biomed Sci Appl; 1997 Jan; 688(1):101-6. PubMed ID: 9029319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.